ViroGates A/S

ViroGates A/S Total Assets

The Total Assets of ViroGates A/S (VIRO.CO) as of Nov 22, 2026 is 30.59 M DKK. In the previous year, Total Assets was 17.66 M DKK — a change of 73.21% (higher).

Total Assets

30.59 MDKK

YoY

73.21%

Last updated:

Total Assets of ViroGates A/S is 2025 30.59 M DKK. Total Assets of ViroGates A/S was 2024 17.66 M DKK. It decreases by 73.21% higher compared to the previous year.

The ViroGates A/S Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
63.42 M DKK
Jan 1, 2019
45.16 M DKK
Jan 1, 2020
38.25 M DKK
Jan 1, 2021
20.23 M DKK
Jan 1, 2022
17.54 M DKK
Jan 1, 2023
24.56 M DKK
Jan 1, 2024
17.66 M DKK
Jan 1, 2025
30.59 M DKK
The ViroGates A/S Total Assets history
YEARTotal AssetsYoY
30.59 MDKK+73.21%
17.66 MDKK-28.08%
24.56 MDKK+40.00%
17.54 MDKK-13.30%
20.23 MDKK-47.11%
38.25 MDKK-15.30%
45.16 MDKK-28.80%
63.42 MDKK+1,174.07%
4.98 MDKK-58.51%
12.00 MDKK-31.11%
17.41 MDKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViroGates A/S stock

Total Assets of ViroGates A/S is 30.59 M DKK in 2025.

Total Assets of ViroGates A/S changed from 17.66 M DKK to 30.59 M DKK, representing a 73.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's ViroGates A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViroGates A/S

All Key Metrics — ViroGates A/S